Compare Navan Inc. Class A Common Stock (NAVN) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Navan Inc. Class A Common Stock vs Tango Therapeutics Inc. — how do they compare? Navan Inc. Class A Common Stock trades at $23.66 (market cap $6.22B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Navan Inc. Class A Common Stock is the larger of the two by market cap, and Tango Therapeutics Inc. is more actively traded (9,619,106 versus 2,173,244). Which is the better fit depends on your goals — on Pluang, investors hold Navan Inc. Class A Common Stock for 6 Days and Tango Therapeutics Inc. for 0 Days on average.
| NAVN | TNGX | |
|---|---|---|
Market Cap | $6.22B | $3.75B |
Volume | 2,173,244 | 9,619,106 |
Sector | Technology | Health |
52-Week High | $30.58 | $32.90 |
52-Week Low | $8.51 | $7.50 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $5.57B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Navan (NAVN) trades at $23.9, up 1.44% on the day, with a bullish technical signal from moving averages but overbought oscillators. The company reported strong revenue growth of 35% year-over-year in Q2 2027 to $233 million, beating earnings expectations, yet remains unprofitable with a net income margin of -42.11%. Recent developments include the acquisition of BoomPop and a partnership with Engine to expand its AI-powered travel platform.
The outlook is mixed: unanimous analyst buy ratings and a $30.56 price target suggest 27.5% upside, driven by growth execution. However, high debt, persistent losses, insider selling, and ongoing legal investigations pose significant risks. The stock's valuation appears stretched given current profitability challenges.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Navan Inc. Class A Common Stock
Navan provides an AI-powered platform for business travel, payments, and expense management. Its tools support trip booking, policy controls, payment processing, expense reconciliation, and reporting.
Read more on NAVN →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
